Morepen Laboratories LimitedQ1 FY27 Results & Financial Update
Morepen Laboratories Limited: Q1 FY27 consolidated results and company financials – revenue ₹570.13 Cr, PAT ₹56.35 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceReported figures and period changes.Changes compare like-for-like reported periods where available.
Find an answer
Ask this result
Chart · Market context
Morepen Laboratories price & chart
Market priceLoading…
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Morepen Laboratories Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Morepen Laboratories reported consolidated total income of INR 575.31 crore for the quarter ended 30 June 2026, comparing favorably with INR 413.90 crore in the corresponding period of the previous year and INR 588.37 crore in the preceding quarter ended 31 March 2026.
Net profit after tax attributable to owners reached INR 56.40 crore for Q1 FY27, surging substantially from INR 10.75 crore in Q1 FY25 (year-ago) and INR 15.74 crore in Q4 FY26, driven by enhanced operating leverage, strong export demand, and the commercial rollout of key manufacturing contracts.
The company's press release highlighted that consolidated revenue from operations reached INR 575.31 crore, reflecting a 34% year-on-year increase, while EBITDA jumped 207% year-on-year to INR 87.72 crore with EBITDA margin improving to 15.25% from 6.65% in Q1 FY26.
Operating performance during the quarter benefited significantly from the full-scale commercialization of Morepen's previously announced INR 825 crore CDMO mandate, which contributed INR 58 crore in commercial supplies during the quarter under review.
Total quarterly expenses stood at INR 500.78 crore compared to INR 414.13 crore in the year-ago quarter, with cost of materials consumed at INR 328.38 crore, employee benefit expenses at INR 62.44 crore, and selling and distribution expenses at INR 53.31 crore.
Finance costs for the quarter were recorded at INR 4.84 crore, while depreciation and amortization expenses stood at INR 8.35 crore. Tax expenses for the quarter totaled INR 18.18 crore, reflecting higher taxable profits across operating entities.
Basic and diluted earnings per share (EPS) for the consolidated entity stood at INR 1.03 for the quarter, compared to INR 0.20 in the corresponding quarter of the previous year and INR 0.28 in the preceding quarter.
01 · Business model
What does Morepen Laboratories do?
Morepen Laboratories Limited is a vertically integrated pharmaceutical and healthcare company headquartered in Gurugram, Haryana, with manufacturing facilities located primarily in Baddi, Himachal Pradesh. The company has over four decades of operating experience in Active Pharmaceutical Ingredients (APIs) and finished formulations, supplying regulated markets across more than 90 countries.
The company operates through two primary revenue engines: its traditional and evolving API manufacturing business—supported by process chemistry and complex molecule capabilities—and its rapidly scaling Medical Devices division focused on chronic-care diagnostics such as blood glucose meters, blood pressure monitors, and related consumables.
Morepen has progressively transitioned its business model under its 'Morepen 2.0' strategy, moving from standard commodity API sales toward long-duration Contract Development and Manufacturing Organization (CDMO) partnerships, custom synthesis, and recurring consumer healthcare demand.
The corporate group includes several domestic and international subsidiaries such as Morepen Devices Ltd., Morepen Rx Ltd., Morepen Medipath Ltd., Morepen Bio Inc. (USA), and operational units in Dubai, ensuring direct distribution access across North America, the Middle East, and other global regions.
02 · Historical context
What shaped the business before this quarter
The company established a strong quality foundation by successfully completing four consecutive USFDA inspections with zero Form 483 observations prior to the reporting period.
03 · Financial snapshot
Current quarter vs the two useful baselines
| Metric | Q1 FY27 | Year-ago | Previous quarter |
|---|---|---|---|
| Revenue from operations | ₹570.13 Cr | — | — |
| Total income | ₹575.31 Cr | ₹413.90 Cr | ₹588.37 Cr |
| Profit before tax | ₹74.53 Cr | — | — |
| Profit after tax | ₹56.35 Cr | ₹11.09 Cr | ₹27.27 Cr |
| EPS | ₹1.03 | ₹0.22 | ₹1.46 |
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
The API segment recorded a 31% year-on-year growth during the quarter, supported by base business recovery, improved product mix, customer prioritization, and better operating discipline.
Export revenue surged by 111% year-on-year, led by a 42% growth in API exports, reflecting strengthened traction across regulated international markets.
The INR 825 crore CDMO mandate entered full-scale commercialization during the quarter, delivering INR 58 crore in commercial dispatches and validating the company's shift toward high-value manufacturing.
The medical devices segment continued to act as a second growth engine, registering a 19% year-on-year expansion driven by chronic-care diagnostics and recurring consumables.
What drove margins
EBITDA margin expanded significantly to 15.25% in Q1 FY27 from 6.65% in Q1 FY26, driven by higher operational scale, improved product realization, and better cost absorption.
Cost of materials consumed stood at INR 328.38 crore, reflecting scaling manufacturing operations alongside increased procurement to service expanding order books.
Selling and distribution expenses were reported at INR 53.31 crore for the quarter, supporting broader domestic and international market reach for both pharmaceuticals and medical devices.
05 · Demand, customers & order book
Where demand is coming from
The company's INR 825 crore CDMO mandate transitioned into active commercial execution, with initial commercial dispatches totaling INR 58 crore completed during the quarter.
06 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
The company operates primarily within the pharmaceutical business segment, encompassing active pharmaceutical ingredients, finished formulations, and CDMO services.
The medical devices platform maintains a reported installed base of 20 million blood glucose meters and an annual strip manufacturing scale of 500 million strips, securing recurring consumable demand.
Geography and market mix
Morepen exports its products to over 90 countries, supported by wholly-owned and operational foreign subsidiaries including Morepen Bio Inc. in the USA and trading entities in Dubai.
07 · Capacity, projects & execution
What is being built, commissioned or delivered
Capacity, production and utilisation
To accommodate larger global CDMO opportunities, Morepen is expanding its manufacturing capacity in phases, with a stated roadmap targeting up to 1,200 KL by FY30.
08 · Strategy & new businesses
How the company is trying to change its growth mix
The company is advancing its Morepen 2.0 strategy, shifting from transaction-led commodity APIs to an innovation-led manufacturing platform focusing on small molecules, complex chemistry, advanced intermediates, and high-potency manufacturing.
The board progressed with steps for the proposed hiving off of the Medical Devices Business into subsidiary Morepen Medipath Limited on a slump sale basis, subject to shareholder approvals at the upcoming AGM.
09 · Reported developments
What changed operationally
Morepen completed its fourth consecutive USFDA inspection with zero Form 483 observations, reinforcing customer confidence and regulatory standing.
The company delivered record quarterly revenue of INR 575.31 crore and a net profit after minority interest of INR 56.40 crore, supported by robust demand across business verticals.
10 · Beyond the numbers
What changed beyond the numbers
Reported update
Management Re-appointment
The board approved the re-appointment of Mr. Sushil Suri as Chairman & Managing Director for a further three-year term effective from 20 October 2026, subject to shareholder approval.
Reported update
Dividend Record Date
The board fixed Saturday, 19 September 2026, as the record date for determining members eligible for the final dividend for the financial year ended 31 March 2026, pending AGM approval.
11 · Previous-quarter changes
What changed since the previous quarter
Consolidated PAT after minority interest increased from INR 15.74 crore in Q4 FY26 to INR 56.40 crore in Q1 FY27, reflecting improved operational profitability.
12 · Key Q&A
The quarter, answered directly
What does Morepen Laboratories do?
Morepen Laboratories Limited is a vertically integrated pharmaceutical and healthcare company headquartered in Gurugram, Haryana, with manufacturing facilities located primarily in Baddi, Himachal Pradesh. The company has over four decades of operating experience in Active Pharmaceutical Ingredients (APIs) and finished formulations, supplying regulated markets across more than 90 countries.
What is the clearest takeaway from Q1 FY27?
Morepen Laboratories reported consolidated total income of INR 575.31 crore for the quarter ended 30 June 2026, comparing favorably with INR 413.90 crore in the corresponding period of the previous year and INR 588.37 crore in the preceding quarter ended 31 March 2026.
What drove revenue or demand?
The API segment recorded a 31% year-on-year growth during the quarter, supported by base business recovery, improved product mix, customer prioritization, and better operating discipline.
What mattered most for margins or profitability?
EBITDA margin expanded significantly to 15.25% in Q1 FY27 from 6.65% in Q1 FY26, driven by higher operational scale, improved product realization, and better cost absorption.
What changed operationally beyond the headline numbers?
To accommodate larger global CDMO opportunities, Morepen is expanding its manufacturing capacity in phases, with a stated roadmap targeting up to 1,200 KL by FY30.
What should the next disclosure help confirm?
Monitor the continued execution and commercial dispatch milestones associated with the INR 825 crore CDMO mandate.
13 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
14 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
CDMO Scale-up Progress: Monitor the continued execution and commercial dispatch milestones associated with the INR 825 crore CDMO mandate.
- 02
Capacity Expansion Execution: Track progress on the phased manufacturing capacity roadmap targeting up to 1,200 KL by FY30.
- 03
Medical Devices Growth Trajectory: Observe ongoing adoption trends in chronic-care medical devices and consumable strip volumes.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.